NEW YORK (CBSNewYork)-- Abdominal aortic aneurysm is a life-threatening condition that affects more than 3 million Americans annually and can kill up to 90% of people who have it, but it's almost ...
The US Food and Drug Administration (FDA) is reminding clinicians about the need for "at least yearly, lifelong follow-up" to monitor for type III endoleaks in patients with any type of Endologix AFX ...
Nectero Medical Inc. has secured $19.5 million in a series C financing round, led by Boston Scientific Corp. The company is developing the Endovascular Aortic Stabilization Treatment (EAST) system, a ...
For the second time this year, the US Food and Drug Administration has issued a safety communication to healthcare professionals regarding risk of Type III endoleaks associated with Endologix AFX ...
That women fare worse than men after treatment for abdominal aortic aneurysm isn’t news, but 10 years’ worth of US registry data show that the difference is long-lasting and appears restricted to ...
"Abdominal Aortic Aneurysm Market Insight, Epidemiology And Market Forecast - 2034"The abdominal aortic aneurysm treatment market is experiencing significant expansion, driven by increasing disease ...
Abdominal aortic aneurysm, a weakening and ballooning of the aorta, the largest blood vessel in the body, may result in a life-threatening rupture. In a small, preliminary study examining a potential ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback